A Phase 3 interventional study of Atogepant in Episodic Migraine, sponsored by Allergan. Completed at 113 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-05-12.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.
Among the 21 studies testing atogepant in Migraine Disorders, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 15 in phase 3, and was the 5th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18–70
AbbVie · Sites in United States, Canada, Denmark and 8 more countries
Ages 12–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
AbbVie · Sites in United States, Belgium, Canada and 13 more countries
Ages 6–17
Konrad Peter Weber · Sites in Switzerland
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 16 · Phase 4 4
First in 2016; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 685 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 468 across the 21 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 5 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
55 studies in Migraine Disorders by AbbVie: 9 open now, 13 under way, 7 of them phase 3. Of 40 finished, 32 (80%) have results posted.
Among the 55 studies in Migraine Disorders by AbbVie, this one is the 16th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2019, is one of 30 in phase 3, and was the 26th registered.
AbbVie’s Migraine Disorders studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing atogepant in Migraine Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received atogepant 60 mg, orally, once daily (QD) for up to 40 weeks.
Drug: Atogepant
Atogepant Tablets
Percentage of Participants With at Least 1 Treatment-Emergent Adverse Event and Treatment-Emergent Serious Adverse Event (TEAEs/TESAEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
Time frame: From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44)
Percentage of Participants With Potentially Clinically Significant (PCS) Laboratory Values as Assessed by the Investigator
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.
Time frame: Up to Week 44
Percentage of Participants With Potentially Clinically Significant (PCS) Electrocardiograms (ECGs) Findings as Assessed by the Investigator
12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to Week 40
Percentage of Participants With Potentially Clinically Significant (PCS) Vital Sign Measurements as Assessed by the Investigator
PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
Time frame: Up to Week 44
Number of Participants With Suicidal Ideation and Behaviour Using 5-Point Scale of Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
Time frame: OL Treatment Period: Up to Week 40; Safety Follow-up Period: Week 44
| Milestone | Atogepant 60 mg |
|---|---|
| Started | 685 |
| Completed | 511 |
| Not completed | 174 |
| Withdrew: Withdrawal criteria at visit 1 | 43 |
| Withdrew: Adverse event | 25 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Withdrawal by subject | 35 |
| Withdrew: Lost to follow-up | 19 |
| Withdrew: Pregnancy | 3 |
| Withdrew: Protocol deviation | 16 |
| Withdrew: Non-compliance with study drug | 4 |
| Withdrew: Site terminated by sponsor | 3 |
| Withdrew: Reason not specified | 22 |
| Milestone | Atogepant 60 mg |
|---|---|
| Started | 640 |
| Completed | 624 |
| Not completed | 16 |
| Withdrew: Withdrawal by subject | 12 |
| Withdrew: Lost to follow-up | 4 |
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug.
| percentage of participants | Atogepant 60 mg |
|---|---|
| TEAEs | 62.5 |
| TESAEs | 3.4 |
Clinical laboratory test values are considered PCS if they meet either the lower-limit or higher-limit PCS criteria defined in the categories below. Percentage of participants with PCS laboratory values are summarized for chemistry, hematology, and urinalysis. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during post-baseline are reported.
| percentage of participants | Atogepant 60 mg |
|---|---|
| Eosinophils Absolute Cell Count (10^9/L): > 2.0 × Upper Limit of Normal (ULN) | 0.3 |
| Hematocrit (Ratio): < 0.9 × Lower Limit of Normal (LLN) | 1.5 |
| Hematocrit (Ratio): > 1.1 × ULN | 0.3 |
| Hemoglobin (g/L): < 0.9 × LLN | 2.2 |
| Lymphocytes Absolute Cell Count (10^9/L): < 0.7 × LLN | 0.6 |
| Lymphocytes Absolute Cell Count (10^9/L): > 1.3 × ULN | 0.3 |
| Monocytes Absolute Cell Count (10^9/L): < 0.5 × LLN | 0.3 |
| Neutrophils Absolute Cell Count (10^9/L): < 0.7 × LLN | 1.6 |
| Neutrophils Absolute Cell Count (10^9/L): > 1.3 × ULN | 4.4 |
| Platelet Count (Thrombocytes) (10^9/L): < 0.5 × LLN | 0.1 |
| Platelet Count (Thrombocytes) (10^9/L): > 1.5 × ULN | 0.3 |
| Red Blood Cell Count (10^12/L): < 0.9 × LLN | 2.4 |
| Red Blood Cell Count (10^12/L): > 1.1 × ULN | 0.1 |
| White Blood Cell Count (10^9/L): < 0.9 × LLN | 3.5 |
| White Blood Cell Count (10^9/L): > 1.5 × ULN | 0.6 |
| Alanine Aminotransferase (SGPT) (U/L): ≥ 3.0 × ULN | 0.3 |
| Aspartate Aminotransferase (SGOT) (U/L): ≥ 3.0 × ULN | 0.4 |
| Bicarbonate (HCO3) (mmol/L): < 0.9 × LLN | 0.7 |
| Bilirubin, Total (umol/L): ≥ 1.5 × ULN | 0.3 |
| Blood Urea Nitrogen (mmol/L): > 1.5 × ULN | 0.1 |
| Creatine Kinase (U/L): > 2.0 × ULN | 5.0 |
| Creatinine (umol/L): > 1.5 × ULN | 0.4 |
| Glomerular Filtration Rate (GFR) Estimated Calculation (mL/min/1.73m^2): < 60 mL/min/1.73m^2 | 15.6 |
| Glucose, Non-fasting (mmol/L): < 0.8 × LLN | 2.2 |
| Glucose, Non-fasting (mmol/L): > 2.0 × ULN | 0.9 |
| Phosphorus (mmol/L): < 0.9 × LLN | 1.6 |
| Phosphorus (mmol/L): > 1.1 × ULN | 0.6 |
| Potassium (mmol/L): > 1.1 × ULN | 2.2 |
| Protein, Total (g/L): < 0.9 × LLN | 0.7 |
| Uric Acid (Urate) (umol/L): > 1.2 × ULN | 0.7 |
| Urine Glucose: At Least 1+ | 0.9 |
| Urine Protein: At Least 1+ | 27.6 |
12-lead ECGs were performed at select study visits. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| percentage of participants | Atogepant 60 mg |
|---|---|
| QRS Duration, Single Beat (msec): ≥ 150 milliseconds (msecs) | 0.3 |
| PR interval, Single Beat (msec): ≥ 250 msecs | 0.5 |
| QTcB interval, Single Beat (msec): > 500 msecs | 0.2 |
| QTcB interval, Single Beat (msec): Increase > 60 msecs | 0.3 |
| QTcF interval, Single Beat (msec): Increase > 60 msecs | 0.2 |
| QTcF interval, Single Beat (msec): >450 msecs | 3.4 |
| QTcF interval, Single Beat (msec): >480 msecs | 0.1 |
PCS postbaseline vital sign values are summarized for categories: systolic and diastolic blood pressures \[sitting and standing\], pulse rate \[sitting and standing\], respiratory rate, temperature, weight. Only those categories where at least 1 person had a non-PCS value at Baseline and met the PCS criterion at least once during postbaseline are reported.
| percentage of participants | Atogepant 60 mg |
|---|---|
| Systolic Blood Pressure Sitting (mmHg): ≤ 90 and Decrease of ≥ 20 | 1.9 |
| Systolic Blood Pressure Standing (mmHg): ≤ 90 and Decrease of ≥ 20 | 0.7 |
| Systolic Blood Pressure Standing (mmHg): ≥ 180 and Increase of ≥ 20 | 0.1 |
| Standing - Sitting Systolic Blood Pressure (mmHg): ≤ -20 | 9.8 |
| Diastolic Blood Pressure Sitting (mmHg): ≤ 50 and Decrease of ≥ 15 | 0.6 |
| Diastolic Blood Pressure Sitting (mmHg): ≥ 105 and Increase of ≥ 15 | 1.0 |
| Diastolic Blood Pressure Standing (mmHg): ≤ 50 and Decrease of ≥ 15 | 0.7 |
| Diastolic Blood Pressure Standing (mmHg): ≥ 105 and Increase of ≥ 15 | 1.5 |
| Standing - Sitting Diastolic Blood Pressure (mmHg): ≤ -15 | 7.4 |
| Pulse Rate Sitting (beats/min): ≤ 50 and Decrease of ≥ 15 | 0.3 |
| Pulse Rate Standing (beats/min): ≤ 50 and Decrease of ≥ 15 | 0.4 |
| Pulse Rate Standing (beats/min): ≥ 120 and Increase of ≥ 15 | 1.8 |
| Standing - Sitting Pulse Rate (beats/min): ≥ 25 | 6.8 |
| Weight (kg): Decrease of ≥ 7 percent (%) | 23.9 |
| Weight (kg): Increase of ≥ 7% | 9.2 |
C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Suicidal ideation: Minimum total score 1, maximum total score 5; higher total scores indicate more suicidal ideation. Suicidal behavior: Minimum total score 0, maximum total score 4; higher total scores indicate more suicidal behavior.
| Participants | Atogepant 60 mg | Safety Follow-up Period |
|---|---|---|
| Suicidal Ideation | 4 | 1 |
| Suicidal Behavior | 0 | 0 |
Collected over From dose of study drug until 30 days following last dose of study drug (up to approximately Week 44). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atogepant 60 mg | 0/685 (0%) | 23/685 (3.4%) | 71/685 (10.4%) |
| Event | Atogepant 60 mg |
|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/685 |
| Road traffic accidentInjury, poisoning and procedural complications | 2/685 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 2/685 |
| GastritisGastrointestinal disorders | 1/685 |
| Non-cardiac chest painGeneral disorders | 1/685 |
| Systemic inflammatory response syndromeGeneral disorders | 1/685 |
| CholelithiasisHepatobiliary disorders | 1/685 |
| Clostridium difficile colitisInfections and infestations | 1/685 |
| Corona virus infectionInfections and infestations | 1/685 |
| Staphylococcal infectionInfections and infestations | 1/685 |
| Event | Atogepant 60 mg |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 38/685 |
| Urinary tract infectionInfections and infestations | 36/685 |
Safety population included all participants who received at least 1 dose of atogepant in this extension study.
| Age, Continuous(years) | Atogepant 60 mg |
|---|---|
| Mean | 41.8 ± 12.30 |
| Sex: Female, Male(Participants) | Atogepant 60 mg |
|---|---|
| Female | 604 |
| Male | 81 |
| Ethnicity (NIH/OMB)(Participants) | Atogepant 60 mg |
|---|---|
| Hispanic or Latino | 54 |
| Not Hispanic or Latino | 631 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Atogepant 60 mg |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 9 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 86 |
| White | 578 |
| More than one race | 8 |
| Unknown or Not Reported | 1 |
Showing the first 100 of 113 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing, please refer to the link below.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · vivli.org
Ran from May 2019 to primary completion in Mar 2021, 22 months.
Results were first posted in May 2022, 1 year 1 month after primary completion.
Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 22 months is above that.
Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant